Eli Lilly and Company (LLY) Unveils AI Platform to Enhance Drug Discovery

Eli Lilly and Co. (NYSE:LLY) is one of the best defensive stocks to buy, according to Steve Cohen. On September 9, the company announced the launch of an artificial intelligence and machine learning platform.

TuneLab is the platform that consists of AI models and proprietary data obtained at a cost of more than $1 billion. The platform is designed to provide biotech companies with all the necessary models trained on years of research data to accelerate drug development.

“Lilly TuneLab was created to be an equalizer so that smaller companies can access some of the same AI capabilities used every day by Lilly scientists,” said chief scientific officer Daniel Skovronsky.

The platform is already attracting interest, with Circle Pharma confirming that it will use it to develop cancer therapies, and Insitro leveraging it to build new AI models for the discovery of small-molecule therapies.

Eli Lilly and Company (NYSE:LLY) is a pharmaceutical company that focuses on discovering, developing, and manufacturing innovative pharmaceuticals to improve people’s health and lives. It produces medicines for conditions such as diabetes, obesity, and cardiovascular disease.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 11 Best Wind Power and Solar Stocks to Buy According to Analysts and 10 Best Robinhood Penny Stocks to Invest In.

Disclosure: None. This article is originally published at Insider Monkey.